---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000136"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:32:43.767742+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arvinas Q2 2025: NDA for vepdegestrant; CEO to retire; cash $861M

## Summary
- Submitted NDA to FDA for vepdegestrant in ESR1m ER+/HER2- advanced breast cancer.
- VERITAC-2 Phase 3: 2.9-month PFS improvement in ESR1m subgroup; ITT not significant.
- Cash $861.2M at June 30, 2025 (down from $1,039.4M); R&D $68.6M Q2 vs $93.7M YoY.
- CEO John Houston to retire; board searching for successor; remains Chair.
- ARV-102 Phase 1: >50% LRRK2 reduction in CSF, >90% in PBMCs; dosing in Parkinson's.

## SEC filing metadata
- accession: 0001655759-25-000136
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000136/0001655759-25-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000136/arvn-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000136
- JSON: https://secwatch.observer/filing/0001655759-25-000136.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.